This study demonstrates that the novel chemiluminescence immunoassay (CLIA) and the conventionally used LFA have a comparable performance in the detection of glucuronoxylomannan in cerebrospinal fluid (CSF) among patients with cryptococcosis. It enables tracking antigen concentration changes during treatment, providing preliminary reference for therapeutic monitoring.
Zhao et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: